What are the recommended starting doses and titration schedules for Latuda (lurasidone) in adults with schizophrenia or bipolar I depression, including adjustments for patients aged 65 years or older, moderate hepatic impairment, and strong CYP3A4 inhibitors or inducers?

Latuda Dosing

For schizophrenia in adults, start Latuda at 40 mg once daily with food (at least 350 calories), with no initial titration required; for bipolar I depression in adults, start at 20 mg once daily. 1

Schizophrenia Dosing

Adults

• Starting dose: 40 mg once daily
• No initial titration required
• Therapeutic range: 40-160 mg/day
• Maximum dose: 160 mg/day 1

Adolescents (13-17 years)

• Starting dose: 40 mg once daily
• Therapeutic range: 40-80 mg/day
• Maximum dose: 80 mg/day 1

Bipolar I Depression Dosing

Adults (Monotherapy or Adjunctive with Lithium/Valproate)

• Starting dose: 20 mg once daily
• No initial titration required
• Therapeutic range: 20-120 mg/day
• Maximum dose: 120 mg/day
• Important caveat: Higher doses (80-120 mg/day) did not provide additional efficacy compared to lower doses (20-60 mg/day) in monotherapy studies 1
• Optimal dose based on recent evidence: 40-60 mg/day provides the best balance of efficacy and tolerability 2

Pediatric Patients (10-17 years)

• Starting dose: 20 mg once daily
• Titration: May increase after one week based on clinical response
• Therapeutic range: 20-80 mg/day
• Maximum dose: 80 mg/day
• Clinical note: 67% of patients in trials received 20-40 mg/day 1

Critical Administration Requirement

Latuda MUST be taken with food (at least 350 calories). This is non-negotiable—administration with food increases AUC by 2-fold and Cmax by 3-fold. Without food, the drug is substantially under-absorbed and will likely be ineffective 1.

Dose Adjustments for Special Populations

Elderly Patients (≥65 years)

• Recommended range: 20-80 mg/day (lower than standard adult dosing) 3
• Rationale: Reduced clearance and increased sensitivity to adverse effects in elderly populations

Moderate Hepatic Impairment (Child-Pugh Score 7-9)

• Starting dose: 20 mg/day
• Maximum dose: 80 mg/day 1

Severe Hepatic Impairment (Child-Pugh Score 10-15)

• Starting dose: 20 mg/day
• Maximum dose: 40 mg/day 1

Moderate Renal Impairment (CrCl 30 to <50 mL/min)

• Starting dose: 20 mg/day
• Maximum dose: 80 mg/day 1

Severe Renal Impairment (CrCl <30 mL/min)

• Starting dose: 20 mg/day
• Maximum dose: 80 mg/day 1

Drug Interaction Adjustments

Strong CYP3A4 Inhibitors

Contraindicated—do not use Latuda with strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil) 1

Moderate CYP3A4 Inhibitors

• Starting dose: 20 mg/day
• Maximum dose: 80 mg/day
• Examples include diltiazem, erythromycin, fluconazole, verapamil 1

Strong CYP3A4 Inducers

Contraindicated—do not use Latuda with strong CYP3A4 inducers (rifampin, avasimibe, St. John's Wort, phenytoin, carbamazepine) as they significantly reduce lurasidone levels 1

Practical Titration Strategy for Acute Schizophrenia

Recent evidence suggests an individualized approach to starting dose in acute schizophrenia:

• Start at 80 mg/day when rapid control of positive symptoms or agitation is needed and the patient can tolerate it (produces earlier symptom reduction without increased discontinuation) 4
• Start at 40 mg/day when akathisia risk is a concern or patient preference argues for caution, with planned day-7 review for up-titration 4

Common Pitfalls to Avoid

1. Forgetting food requirement: This is the most common error—patients must take Latuda with at least 350 calories or absorption is inadequate
2. Over-dosing in bipolar depression: Doses above 60 mg/day don't add efficacy but increase side effects 2
3. Missing drug interactions: Always check for CYP3A4 inhibitors/inducers before prescribing
4. Not adjusting for hepatic/renal impairment: These patients need lower starting doses and maximum doses

Side Effect Profile by Dose

• Most common adverse effects: Somnolence, akathisia, nausea, parkinsonism 5
• Side effects increase with higher doses (50 mg: RR 1.15; 100 mg: RR 1.18) 2
• Weight gain: Minimal, occurs primarily at doses <60 mg (approximately 0.38 kg at 40 mg) 2
• Glucose elevation: Occurs at doses >70 mg 2
• Prolactin elevation: Dose-dependent increase in both males and females 2
• Metabolic profile: Highly favorable compared to other second-generation antipsychotics—no clinically meaningful alterations in lipids or ECG QTc interval 5, 6

Pharmacogenetic Considerations

Patients with CYP3A4 rs2242480 CC genotype have 25% lower clearance than TT carriers, which may warrant lower doses if genotyping is available 7. However, routine genotyping is not currently standard practice.